-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AMO-01 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMO-01 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMO-01 in Epilepsy Drug Details: AMO-01 (TLN-4601) is under development for the treatment...
-
Product Insights
John E Amos Power Plant
John E Amos Power Plant is a thermal project located in West Virginia, United States. The project is owned by Appalachian Power. The project came online in 1971. Empower your strategies with our John E Amos Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tideglusib in Myotonic Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tideglusib in Myotonic Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tideglusib in Myotonic Dystrophy Drug Details: Tideglusib (AMO-02/NP-12) is under development for...
-
Product Insights
Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) - Drugs In Development, 2023’, provides an overview of the Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Phelan-McDermid Syndrome (22q13.3 Deletion Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Rett Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Rett Syndrome - Drugs In Development, 2023’, provides an overview of the Rett Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rett Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Myotonic Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Myotonic Dystrophy - Drugs In Development, 2023’, provides an overview of the Myotonic Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
United States (US) Thermal Power Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
United States (US) Thermal Power Market Report Overview The cumulative capacity for thermal power in the US was 808.9 GW in 2022. It is expected to achieve a negative CAGR of less than 1% during 2022-2035. The US thermal power market research report highlights installed capacity and power generation trends from 2010 to 2035. The report discusses the key insights about the major active and upcoming thermal power plants in the US. US Thermal Power Market Outlook, 2022-2035 (GW) Buy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritumumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritumumab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritumumab in Non-Small Cell Lung Cancer Drug Details: Pritumumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritumumab in Anaplastic Astrocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritumumab in Anaplastic Astrocytoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritumumab in Anaplastic Astrocytoma Drug Details: Pritumumab is under development for the...